MMA Embolization for Refractory Chronic Migraine
ConditionMigraine Disorders
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorCerenovus, Part of DePuy Synthes Products, Inc.
About this trial
This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic migraine.
Eligibility criteria
Qualifiers
Patient is between 18 and 65 years of age (inclusive) at the time of consent
Age of onset of Chronic Migraine <= 64 years
Age of onset of migraine diagnosis < 50 years
Patient has a current diagnosis of refractory migraine
Disqualifiers
Patients with a history for the last 2 years of other primary headache types, or secondary headache types except medication overuse headache
Patients with diagnosis of hemiplegic migraine or migrainous infarct
Patients with current regular use of Opioids, Cannabis, Medical Marijuana, etc
Women who are pregnant, lactating, or who are of childbearing age
Trial design
Treatments tested in this trial
- Middle Meningeal Artery embolization
Treatment groups
No treatment groups listed
Locations
9Arizona
Barrow Neurological Institute at St. Joseph's Hospital85013, Phoenix United States
California
John Muir Physician Network Clin. Research Center94598, Walnut Creek United States
Connecticut
Hartford Hospital06032, Hartford United States
New York
University of Buffalo Medical Center14203, Buffalo United States
Sponsors and collaborators
Cerenovus, Part of DePuy Synthes Products, Inc.
Lead sponsor
Source ClinicalTrials.gov